IMOGAM® Rabies-HT

Rabies Immune Globulin (Human) Heat Treated, IMOGAM® Rabies HT, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with Rabies Vaccine prepared from human diploid cells (HDCV) in a pre-exposure or post-exposure treatment series should receive only vaccine. Persons who have been previously immunized with Rabies Vaccines other than HDCV, RVA (Rabies Vaccine Adsorbed), or PCEC (Purified Chick Embryo Cell Vaccine) vaccines should have confirmed adequate rabies antibody titers if they are to receive only vaccine.

IMOGAM® Rabies HT should be injected as promptly as possible after exposure along with the first dose of vaccine. If initiation of treatment is delayed for any reason, IMOGAM® Rabies HT and the first dose of vaccine should still be given, regardless of the interval between exposure and treatment. IMOGAM® Rabies HT may be given up to eight days after the first dose of vaccine was given.

For indications, dosing and other information, please refer to the prescribing information.

IMOGAM® Rabies-HT ‐ Sanofi Pasteur

Size:
2 mL vial
NDC #:
49281-0190-20
Download:
PI
Size:
10 mL vial
NDC #:
49281-0190-10
Download:
PI